Nitroxazepine (brand name Sintamil) is a tricyclic antidepressant (TCA) which was introduced by Ciba-Geigy (now Novartis) for the treatment of depression in India in 1982.[1] It is also indicated for the treatment of nocturnal enuresis.[1] Nitroxazepine acts as a serotonin-norepinephrine reuptake inhibitor and has similar effects to imipramine, but with certain advantages, such as lower anticholinergic side effects.[2][3][4]
Clinical data | |
---|---|
Trade names | Sintamil |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H19N3O4 |
Molar mass | 341.367 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ a b Progress in Medicinal Chemistry, Volume 22 (v. 22). Elsevier Science Publishing Company. 1985. p. 246. ISBN 0-444-80668-7.
- ^ Progress in Medicinal Chemistry, Volume 23 (v. 23). Not Avail. 2000. p. 136. ISBN 0-444-80802-7.
- ^ Ann Reports Medicinal Chem V11 (v. 11). Boston: Academic Press Inc. 1976. p. 4. ISBN 0-12-040511-3.
- ^ Johnson O, Jones DW, Nagarajan K, Bhadbhade MM, Venkatesan K (1992). "X-ray crystal structure analysis of nitroxazepine: 10-(3-dimethylaminopropyl)-2-nitro-10,11-dihydrodibenz [b,f][l,4]oxazepin-11-one". Journal of Chemical Crystallography. 22 (5): 579–583. doi:10.1007/BF01161343. S2CID 96236391.